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Differential effects of staurosporine analogues on cell cycle, growth and
viability in A549 cells
C Courage, R Snowden and A Gescher
Medical Research Council Toxicology Unit, University ofLeicester, PO Box 138, Leicester LE] 9HN, UK.
Summary Staurosporine is a potent but non-specific kinase inhibitor. It has served as synthetic template for a
variety of analogues with high specificity for protein kinase C (PKC). Here staurosporine and four PKC-
selective analogues, the indolocarbazoles, UCN-01 and CGP 41251, and the bisindolylmaleimides, Ro 31-8220
and GF 109203X, were investigated as growth inhibitors of human-derived A549 human lung adenocarcinoma
cells. They were compared with respect to (1) effect on the cell cycle, (2) time dependency of growth arrest and
(3) cytotoxic potency. Cells were exposed for 1, 2 and 4 days, or for 6, 12 and 24 h in the case of cycle-
synchronised cells, to staurosporine analogues at concentrations at which they inhibited growth by 80% after 4
day exposure. Staurosporine and UCN-01 retarded cells in Go/, and CGP 41251 appeared to inhibit cell
growth without cell cycle specificity. Ro 31-8220 slowed progression of synchronised cells through the cycle;
over a longer time period it induced a weak block in G2/M. GF 109203X induced potent G2/M arrest in
synchronised cells. This was not so apparent in asynchronous cells, which by day 4 were slowed in Go/, instead.
Growth arrest induced by these inhibitors was more potent after incubation for 4 rather than 2 days.
Incubation for 1 day followed by maintenance in drug-free medium for 3 days was sufficient to exert some
cytostasis. The differences between cytotoxic and cytostatic concentrations, the former measured by release
from cells of lactate dehydrogenase, were 15 000-fold for staurosporine, 300-fold for UCN-01, -400-fold for
CGP 41251, 25-fold for Ro 31-8220 and -4-fold for GF 109203X. The results show that PKC-selective
staurosporine analogues differ with respect to the mechanisms by which they interfere with the cell cycle. The
necessity of long-term exposure for effective growth inhibition and the considerable margin between cytostatic
and acute cytotoxic indolocarbazole concentrations are findings which might influence the planning and
interpretation of clinical trials of these kinase inhibitors.
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Cellular proliferation and differentiation are regulated by
signals which are transduced via complicated cascades of
biochemical events yielding changes in the phosphorylation
state of key regulatory proteins. Many human cancers are
characterised by aberrant components of their signal
transduction machinery, and clinical and experimental
studies have highlighted the importance of expression of
protein kinases in neoplastic growth (Hennipman et al., 1989;
O'Brian and Ward, 1989). Therefore, agents which interrupt
signalling pathways by inhibition of protein kinases are
attractive targets in contemporary anti-cancer drug discovery
programmes (Powis, 1992). The potent, but non-specific
kinase inhibitor, staurosporine, has served as the parent
molecule for the synthesis of a variety of analogues with
differential inhibitory specificities for protein tyrosine kinases
and protein kinase C (PKC) (Tamaoki and Nakano, 1990;
Toullec et al., 1991; Davis et al., 1992; Trinks et al., 1994).
Two of these agents, the PKC-selective indolocarbazoles,
UCN-01 and CGP 41251, are currently undergoing clinical
evaluation as anti-cancer drugs. Both compounds have been
shown to possess antineoplastic activity in a variety of
tumour systems in mice (Akinaga et al., 1991; Meyer et al.,
1989). CGP 41251 is also a potent modulator of multidrug
resistance in vitro and in vivo (Utz et al., 1994). While it is
assumed that the ability to inhibit PKC is an important
determinant of the antiproliferative and chemomodulatory
properties of this type of agent, ultimate proof for this
contention is lacking. Here, staurosporine and four of its
analogues, Ro 31-8220, GF 109203X, UCN-01 and
CGP 41251, all with similar PKC-inhibitory potency, but
variable specificity for PKC (for structures see Figure 1), were
investigated. The hypothesis was tested that they inhibit cell
growth via similar mechanisms. The following properties
were compared: (1) their effects on the cell cycle at
equicytostatic concentrations; (2) the time dependency and
reversibility associated with their cytostatic properties; and
(3) their acute cytotoxic potential. The investigations were
performed using human-derived A549 lung carcinoma cells,
the growth of which has been shown to be sensitive towards
PKC inhibitors (Courage et al., 1995).
Materials and methods
Drugs and reagents
UCN-01, CGP 41251 and Ro 31-8220 were provided by
Kyowa Hakko Kogyo (Tokyo, Japan), Ciba Geigy (Basle,
Switzerland) and Roche Research Centre (Welwyn Garden
City, UK) respectively. GF 109203X was acquired from
Calbiochem-Novabiochem (Nottingham, UK). Other drugs
and reagents were purchased from Sigma (Poole, UK). Stock
solutions of compounds were prepared in dimethyl sulph-
oxide (DMSO) and stored at -20°C. The final concentration
of DMSO did not exceed 0.3%. In control experiments this
concentration of DMSO did not affect cell growth.
Cell culture
Human-derived A549 lung adenocarcinoma cells were
obtained from the European Collection of Animal Cell
Culture (Salisbury, UK). Cells were maintained in Ham's
F-12 medium supplemented with 10% fetal calf serum (FCS)
(Imperial Laboratories Europe, Andover, UK), penicillin
(100 units ml- ), streptomycin (100 Mg ml-') and glutamine
(2 mM) in an atmosphere of 5% carbon dioxide. Growth
studies were carried out using 6-well multidishes (Nunclon,
Gibco, Paisley, UK).
To investigate the time dependency of the growth arresting
potency of the compounds, cells were counted after exposure
to agents for 2 or 4 days. Cells were seeded at 8 and 2 x 104
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Figure 1 Structures of staurosporine and its four analogues used in this study.
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Figure 2 Flow cytometric analysis of cellular DNA content in A549 cells (a) in the absence (control) or presence of staurosporine,
UCN-01 and Ro 31-8220 after exposure for 1 day, and (b) in the presence of CGP 41251 and GF 109203X after exposure for 1, 2
and 4 days. DNA histograms for cells exposed to staurosporine, UCN-01 and Ro31-8220 on days 2 and 4 were similar to those
shown in a. Results are representative of three independent experiments. For details of flow cytometric analysis see Materials and
methods.
per well for the 2 and 4 day experiments, respectively, to
ensure that similar cell numbers were found in control
cultures at both time points. Drug concentrations were
between 2 and 5 times the concentration which caused 50%
growth inhibition (IC50) after 4 days (Courage et al., 1995).
To ascertain whether inhibition of cell growth was
reversible, cells were seeded at 2 x 104 per well, to which
drug was added 4 h later. Cells were maintained in medium
containing drug for 4 days, or they were washed after 1 day
to remove drug and grown in drug-free medium for a further
3 days. Cells were detached from the wells by trypsinisation
and counted using a Coulter Counter model ZM.
Cell cycle analysis
Cells were exposed for 1, 2 or 4 days to staurosporine
(0.005 gM), UCN-01 (0.1 Mm), CGP 41251 (0.14 gM), Ro 31-
8220 (1.6 gM) and GF 109203X (12 pM). These concentra-
tions are the respective IC80 values established after 4 day
exposure (Courage et al., 1995). At the end of the exposure
time the cells, which were subconfluent, were harvested by
trypsinisation and centrifugation (200 g for 5 min), fixed with
ice-cold 70% ethanol, centrifuged at 600 g for 10 min and
resuspended in 800 MI phosphate-buffered saline (PBS). To
this cell suspension, 100 MI each of solutions of ribonuclease
A (10 mg ml-1) and propidium iodide (50 Mg ml-') were
added, and the mixture was incubated for 30 min at 37°C.
Samples were kept at 4°C until analysis. A FACscan flow
cytometer (Becton Dickinson) with LYSYS II software was
used to quantitate cellular DNA. Using doublet discrimina-
tion, data from 104 singlet cells were acquired and displayed
as histogram of red (propidium iodide) fluorescence. Analysis
of the DNA histograms was performed using CELLFIT
software (Becton Dickinson).
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Figure 3 Cycle distribution of A549 cells after 1, 2 and 4 days exposure to staurosporine (0.005upM), UCN-01 (0.1 Mm), CGP41251
(0.14MgM), GF 109203X (I2gM) and Ro 31-8220 (1.6 Mm). Results are expressed as percentage difference from control cells and are
the mean +s.d. of three experiments. Cell cycle distribution (in %) in control cells was as follows: 59.6+0.9 for Go/,, 29.8 +2.6 for
S, 10.6+2.1 for G2/M after 1 day; 63.3+2.0 for Go/, 25.5+0.9 for S and 10.8 + 1.1 for G2/M after 2 days; 67.6+2.0 for Go/,,
26.3 +3.0 for S and 6.0+5.0 for G2/M after 4 days. Asterisks indicate that values were significantly different from control cultures
(*P<0.05; **P<0.005). For details of flow cytometric analysis see Materials and methods.
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Cells were synchronised in M-phase with nocodazole
(0.4 Mg ml-'), a reversible inhibitor of mitotic spindle
formation, or in early S-phase with aphidicolin (2 mg ml-'),
a reversible DNA polymerase inhibitor, for 12 h. Subse-
quently, cells were washed, transferred to fresh medium with
or without staurosporine analogue, fixed and analysed.
Cytotoxicity assay
The cytotoxic potential of the compounds was established by
measurement of release of lactate dehydrogenase (LDH) from
cells grown in 24-well multidishes, using a LDH assay kit
(Sigma). Cells were seeded at 7 x 104 per well and left for 24 h
after which they were incubated for a further 24 h with drug
at several concentrations in 0.5 ml medium containing 1%
FCS. The amount of LDH released into the medium was
measured. Intracellular LDH was liberated from cells
adhering to the plate by lysis caused by treatment with
0.1% Triton X100 in PBS (0.5 ml) at 37°C for 30 min. LDH
was determined using a Beckman DU 7500 spectrophometer.
Enzyme leakage is expressed as percentage of total releasable
LDH.
Results
Figure 4 Cycle distribution of A549 cells synchronised for 12h
with aphidicoline after 6, 12 and 24h exposure to CGP41251
(O.14gM), GF 109203X (12gM) and Ro31-8220 (1.6gM). Results
are expressed as percentage difference from control (synchronised)
cells and are the mean of two experiments. Cell cycle distribution
(%) in control cells was as follows: 13.4 for Go/,, 20.4 for S, 65.9
for G2/M after 6h; 81.5 for Go/,, 9.0 for S and 9.5 for G2/M after
12h; 57.6 for Goil, 26.9 for S and 15.5 for G2/M after 24h.
Results similar to those shown here were obtained with cells
synchronised with nocodazole. For details of flow cytometric
analysis see Materials and methods.
The compounds used in this study, staurosporine, UCN-01,
CGP 41251, Ro 31-8220 and GF 109203X, have previously
been shown to arrest the growth of A549 cells with IC50
values ranging from 0.0007 gM (staurosporine) to 7.6 gM
(GF 109203X) (Courage et al., 1995). In those experiments
cell growth was assessed after exposure to the drugs for 4
days (four doubling times), and the indolocarbazoles,
staurosporine, UCN-01 and CGP 41251, were more potently
cytostatic than the bisindolylmaleimides, Ro 31-8220 and
GF 109203X. In the experiments described here, A549 cells
were treated with staurosporine and its analogues for 1, 2 and
4 days and cell cycle distribution was studied. The drug
concentrations used were equivalent to the IC80 values
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Figure 5 Inhibition of growth of A549 cells after exposure for 2 (Cl) or 4 days (0) to staurosporine, UCN-01, CGP41251, Ro 31-
8220 and GF 109203X. Results are the mean +s.d. of three experiments, each conducted in duplicate. For experimental details see
Materials and methods.
established previously for growth inhibition after exposure
for 4 days (Courage et al., 1995). Staurosporine and UCN-01
induced cell accumulation in Go/, (Figures 2 and 3) at all
three time intervals investigated. CGP 41251 retarded cells
weakly in Go/, and G2/M after 4 days, but had little or no
effect on the cell cycle at the earlier time points. Both
bisindolylmaleimides caused a slight increase in number of
cells in G2/M. In the case of GF 109203X this effect
decreased with time, and on day 4 was superseded by weak
retardation in Go/, (Figure 3).
Owing to the subtle nature of the effects observed,
experiments were repeated using synchronised cells. Cells
were exposed to nocodazole for 12 h after which they were
released into medium containing staurosporine, UCN-01 or
CGP 41251 and cell cycle distribution was examined after 6,
12 or 24 h. Similarly, cells were exposed to aphidicolin for
12 h after which they were released into medium containing
CGP 41251, Ro 31-8220 or GF 109203X. Consistent with the
results obtained with asynchronous cells, staurosporine and
UCN-01 inhibited in Go/, (data not shown), whereas
CGP 41251 had no effect on any phase of the cell cycle
(Figure 4). Ro 31-8220-treated synchronised cells pro-
gressed with a delay through all stages of the cycle, and
GF 109203X slowed cells in G2/M at the 12 and 24 h time
points (Figure 4).
Cells treated with aphidicolin, nocodazole and the
staurosporine analogues demonstrated an apparent shift of
the DNA profile to the left compared with control cells. This
phenomenon may be the consequence of a change in DNA
stainability, which has also been observed after arrest of cells
at the G1/S boundary with hydroxyurea (Z Darzynkiewicz,
personal communication).
In the light of the time-dependent effects of the
staurosporine analogues on the cell cycle, it seemed
opportune to investigate how the cytostatic potency of the
drugs is affected by duration of exposure time. Cells were
incubated for 4 days with drug at three concentrations and
cytostasis was compared with that observed after incubation
for 2 days. Figure 5 shows that all five compounds were less
potently growth inhibitory after 2 rather than 4 days,
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indicating time dependency. It has been suggested that
inhibition of growth of some carcinoma cell types, including
the MCF-7 cell line, by UCN-01 is irreversible on removal of
the drug (Seynaeve et al., 1993). In order to investigate
whether this property is a general hallmark of staurosporine
analogues, A549 cells were exposed to drugs either for 4 days
or for 1 day, after which drug was removed and cells
maintained in drug-free medium for 3 days. An 'irreversible
block', such as that observed by Seynaeve et al. (1993) for
UCN-01, did not occur in A549 cells. For all five compounds
short-term treatment furnished weak but persistent cytostasis,
which was less effective than that seen after continuous
exposure for 4 days (Figure 6). In order to rule out an effect
specific to these cells, the experiment was repeated using
MCF-7 cells. Incubation of cells with UCN-01 for 1 or 2
days followed by maintenance in drug-free medium for 4 or 5
days, respectively, was markedly less growth inhibitory than
continuous incubation with drug for 6 days (Figure 7), which
is consistent with the results described above, but incompa-
tible with those obtained by Seynaeve et al. (1993).
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Finally, the concentrations of the staurosporine analo-
gues which cause cytostasis were compared with those
which elicit acute cytotoxicity, as measured by the cellular
release of LDH. The rank order of cytotoxic potency
was staurosporine > UCN-01 > Ro 31-8220 > CGP 41251 >
GF 109203X (Figure 8). Staurosporine was the most potent
inhibitor of cell growth and the most cytotoxic of the five
compounds. Yet the difference between cytotoxic and
cytostatic concentration, the latter adjudged by its IC50
value of 0.65 nM (Courage et al., 1995), was 15 000-fold.
The analogous differences between cytotoxic and cytostatic
concentrations for UCN-01 and Ro 31-8220 were 300- and
25-fold respectively. At 33 gIM, the highest concentration
used in the cytotoxicity assay without encountering
solubility problems, neither CGP 41251 nor GF 109203X
caused marked LDH release. On the assumption that
cytotoxicity occurs at concentrations not far above this
value, the difference between cytostatic and cytotoxic
concentrations is probably -400-fold for CGP 41251, but
only -4-fold for GF 109203X.
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Figure 6 Inhibition of growth of A549 cells caused by exposure to staurosporine, UCN-01, CGP41251, Ro 31-8220 and
GF 109203X after either 4 days (0) or 1 day followed by removal of drug and incubation in drug-free medium for 3 days (El).
Results are the mean +s.d. of three experiments, each conducted in duplicate. For experimental details see Materials and methods.
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Figure 7 Inhibition of growth of MCF-7 cells after exposure for
1 (E), 2 (0) or 6 days (A) to UCN-01. Results are the mean
+ s.d. of three experiments, each conducted in duplicate. For
experimental details see Materials and methods.
Discussion
This study demonstrates that PKC-specific analogues of
staurosporine with close structural similarity differ substan-
tially in their effects on the cell cycle when applied at
concentrations exerting growth arrest of comparable potency.
Staurosporine and UCN-01 arrested cells in Go/,. Ro 31-8220
slowed the transit of synchronised cells through all phases of
the cell cycle, in asynchronous cells a small percentage ofcells
was maintained in G2M. GF 109203X induced a potent G2/
M arrest in synchronised cells, but by day 4 this phenomenon
had been replaced by a weak Go/, block. CGP 41251 had
only an ephemeral effect on the cell cycle, which suggests
that, at the concentration studied, it interferes with cell
growth predominantly in a non-cycle-specific manner.
CGP 41251 behaves differently from the other staurosporine
analogues in other respects. For example, it is the only one of
these agents which failed to cause translocation of PKC-c
from the cytosol to the membrane (Courage et al., 1995). In
the light of the close structural similarity between
CGP 41251, staurosporine and UCN-01 (see Figure 1), these
are intriguing pharmacological differences.
Cell cycle effects of the indolocarbazoles have been
reported before, but in most of the published studies drug
concentrations were considerably higher than those employed
here. For example, staurosporine at 2.2 nM affected cells in
GO/, in non-transformed cells, but not in transformed cells
(Crissman et al., 1991). At 50- 100-fold higher concentrations
it blocked both transformed and non-transformed cells in G2/
M (Crissman et al., 1991; Abe et al., 1991). Staurosporine at
5.8 nM delayed the progress of A431 cells through G2/M
transiently, and beyond 8 h it arrested cells in Go/, (Akinaga
et al., 1994). In contrast, at a 10-fold higher concentration it
caused a profound G2/M block. UCN-01 at 150 nM blocked
MDA MB 468 cells from exiting Go/, and entering S-phase
(Seynaeve et al., 1993). This drug at 260 nM caused
accumulation of A431 cells in Go/,, but at 1.54 ,UM it delayed
G2/M progression transiently up to 12 h, followed by a Go/,
block (Akinaga et al., 1994). CGP 41251 at concentrations
above those employed here has been shown to arrest cell
cycle progression in G2/M, at 0.5 and 1 giM in A549 cells and
in NCI-H520 squamous carcinoma cells (Ikegami et al.,
1996); and at 10 ,uM in ras-transformed rat fibroblasts
(Akinaga et al., 1993). The results presented above, together
with the relevant literature, are consistent with the notion
that accumulation in Go/1 might be important for the
cytostasis exerted by the indolocarbazoles, staurosporine
Figure 8 Cytotoxicity of staurosporine, UCN-01, CGP41251,
Ro31-8220 and GF 109203X in A549 cells as judged by ability to
elicit release of lactate dehydrogenase after exposure for 24h.
Results, which are expressed as percentage of total releasable
enzyme in the cells, are the mean +s.d. ofthree experiments, each
conducted in duplicate. For experimental details see Materials
and methods.
and UCN-01, at low concentrations. Effects of staurosporine
analogues of the bisindolylmaleimide type on the cell cycle
have, to our knowledge, hitherto not been described. Our
results suggest that their primary cell cycle target is probably
G2/M. If inhibition of PKC activity was an important
mechanistic determinant of the antiproliferation elicited by
staurosporine analogues, one might surmise that agents of
similar high specificity for PKC would exert similar effects on
the cell cycle. This was not the case. Therefore, the results
buttress the conclusion that inhibition of PKC per se is not
the primary arbiter of the growth arrest caused by these
compounds. This interpretration is consistent with a recent
investigation in this laboratory which demonstrated that
inhibition of PKC activity could not be directly related to cell
growth arrest induced by these compounds (Courage et al.,
1995).
As PKC is not the prime determinant of the antiproli-
ferative effect of these agents, what are the cellular signalling
elements which are their major targets? Prime candidates are
the cyclin-dependent kinases (cdks), which, in concert with
cyclins, are vital components of the cell cycle machinery
(Norbury and Nurse, 1992). There is some evidence
supporting the notion that staurosporine and UCN-01 affect
growth via cdks and/or cyclins. Staurosporine blocked the
progression of human lymphocytes through Go/, between the
cyclin D and cyclin E restriction points and markedly
suppressed phytohaemagglutinin-stimulated cyclin E expres-
sion (Gong et al., 1994). The staurosporine-induced G2/M
block in transformed cell lines has been shown to be due, at
least in part, to inhibition of p34CdC2 kinase (Gadbois et al.,
1992). UCN-01 at G0O/-arresting concentrations inhibits cdks
2, 4 and 6 and decreases the amount of phosphorylated
retinoblastoma susceptibility gene product (pRB) in A549
cells (Kawikami et al., 1996). It remains to be elucidated
whether CGP 41251 and the bisindolylmaleimides affect
cyclins and/or cdks. The mechanism by which the
indolocarbazoles exert higher growth-inhibitory potency
than the bisindolylmaleimides involves perhaps differential
abilities to interfere with cdks.
All five compounds inhibited cell growth more effectively
after exposure for a longer rather than a shorter time period
and their cytostatic ability was diminished by drug removal
after 1 day. These observations indicate that to achieve
therapeutic efficacy dose schedules might have to be chosen
such that they yield significant drug levels over long periods
of time. Intriguingly, UCN-01 has been shown to interrupt
MCF-7 cell proliferation irreversibly necessitating only brief
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exposure (Seynaeve et al., 1993). which was not seen when
the experiment was repeated in this laboratory. The difference
between this result and that descnrbed by Seynaeve et al.
(1993) may well be rooted in phenotype discrepancies
between MCF-7 cells of different origin. a fact illustrated
most poignantly by the discordant pattern of PKC isoenzyme
expression in MCF-7 cells in different laboratories (Blobe et
al., 1993; Stanwell et al.. 1994).
One advantage of the treatment of cancer with modulators
of signal transduction pathways might be the possibility that
they exert cytostasis and not cytotoxicity. perhaps thus
minimising undue toxicity to the host. It is noteworthy
that. among the agents studied here, the indolocarbazoles
displayed a greater difference between cytostatic and acute
cytotoxic concentrations than the bisindolylmaleimides.
insinuating the possibility of an analogous difference in
safety margins.
In conclusion, the results presented here in concert with
the work cited above suggest that (1) the mechanism via
which bisindolylmaleimides arrest growth are different from
those operative for indolocarbazoles: (2) PKC does not
appear to play an important role in these mechanisms; (3) as
far as the indolocarbazoles are concerned. cellular targets of
CGP 41251 are probably different from those which mediate
the growth effects of staurosporine and UCN-01. The
mechanistic basis of the differences is unresolved. but it
may w-ell involve differential effects on cdks. Preclinical
studies have not been published for Ro 31-8220 and
GF 109203X. only for CGP 41251 and UCN-01 (Meyer et
al.. 1989: Akinaga et al.. 1991). both of which are currently
undergoing clinical evaluation as anti-cancer drugs. So the
conclusions drawn here cannot be interpreted in the light of
established pharmacological differences in vivo. The necessity
of extended exposure time for efficacy and the significant
margin between cytostatic and acute cytotoxic concentrations
might be taken into consideration in forthcoming clinical
trials of this type of antisignalling drug.
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